Table 1 Univariate and multivariate results for Austin-CRC, combined RNSH-CRC + MCO-CRC, and RNSH-CRC cohorts. Adjuvant chemotherapy use was not collected for the RNSH-CRC cohort. *p < 0.05

Age (Decades)

353

1.07

0.93–1.22

0.349

266

1.16

0.97–1.39

0.100

Gender (Female vs. Male)

353

0.69

0.49–0.97

0.032*

266

0.77

0.53–1.14

0.190

Site (Proximal vs. Distal)

353

0.88

0.63–1.23

0.442

266

0.95

0.61–1.47

0.811

T Stage (4 vs. 1–3)

353

2.38

1.69–3.35

< 0.001*

266

1.90

1.28–2.83

0.001*

N Stage (2 vs. 0–1)

353

1.68

1.19–2.36

0.003*

266

1.88

1.24–2.85

0.003*

Nodes Examined (< 12 vs. 12+)

324

1.77

1.17–2.68

0.007*

266

1.79

1.10–2.91

0.018*

Adjuvant Chemotherapy (yes vs. no)

309

0.92

0.63–1.34

0.664

266

0.97

0.60–1.57

0.898

Grade (high vs. low)

350

1.43

1.01–2.03

0.046*

266

1.11

0.70–1.74

0.662

Lymphovascular Invasion (yes vs. no)

353

1.42

1.02–1.99

0.040*

266

1.07

0.73–1.58

0.732

Extramural Venous Invasion (yes vs. no)

353

1.55

1.08–2.21

0.016*

266

1.29

0.85–1.96

0.227

MMR Status (pMMR vs. dMMR)

335

1.61

0.95–2.72

0.074

266

0.77

0.39–1.49

0.431

AI iTIL Risk (high vs. low)

353

2.05

1.46–2.88

< 0.001*

266

2.03

1.35–3.05

< 0.001*

RNSH-CRC + MCO-CRC

5-Year OS

n

HR

95% CI

p

n

HR

95% CI

p

Age (Decades)

1955

1.40

1.29–1.51

< 0.001*

1901

1.51

1.38–1.65

< 0.001*

Gender (Female vs. Male)

1955

0.87

0.73–1.04

0.135

1901

0.80

0.67–0.96

0.016*

Site (Proximal vs. Distal)

1945

1.04

0.87–1.25

0.632

1901

0.98

0.80–1.20

0.861

Stage (III vs. II)

1955

2.31

1.92–2.79

< 0.001*

1901

1.66

1.32–2.08

< 0.001*

T Stage (4 vs. 1–3)

1955

2.39

2.00-2.86

< 0.001*

1901

1.87

1.55–2.27

< 0.001*

N Stage (2 vs. 0–1)

1954

2.56

2.10–3.13

< 0.001*

1901

1.80

1.42–2.29

< 0.001*

Nodes Examined (< 12 vs. 12+)

1954

1.71

1.40–2.10

< 0.001*

1901

1.70

1.37–2.10

< 0.001*

Grade (high vs. low)

1944

1.79

1.49–2.15

< 0.001*

1901

1.31

1.07–1.60

0.009*

Lymphovascular Invasion (yes vs. no)

1945

2.16

1.81–2.58

< 0.001*

1901

1.28

1.03–1.60

0.026*

Extramural Venous Invasion (yes vs. no)

1926

1.91

1.58–2.30

< 0.001*

1901

1.26

1.01–1.57

0.039*

MMR Status (pMMR vs. dMMR)

1951

1.13

0.90–1.42

0.285

1901

1.03

0.79–1.34

0.828

AI iTIL Risk (high vs. low)

1955

1.67

1.39-2.00

< 0.001*

1901

1.37

1.13–1.66

0.001*

RNSH-CRC

5-Year OS

n

HR

95% CI

p

n

HR

95% CI

p

Age (Decades)

1070

1.37

1.23–1.53

< 0.001*

1045

1.50

1.33–1.71

< 0.001*

Gender (Female vs. Male)

1070

1.13

0.88–1.46

0.327

1045

0.98

0.76–1.28

0.902

Site (Proximal vs. Distal)

1063

1.35

1.04–1.74

0.022*

1045

1.22

0.92–1.61

0.168

Stage (III vs. II)

1070

2.76

2.09–3.64

< 0.001*

1045

1.71

1.21–2.42

0.002*

T Stage (4 vs. 1–3)

1070

2.63

2.05–3.38

< 0.001*

1045

1.90

1.45–2.48

< 0.001*

N Stage (2 vs. 0–1)

1069

3.15

2.40–4.14

< 0.001*

1045

2.23

1.61–3.10

< 0.001*

Nodes Examined (< 12 vs. 12+)

1069

1.49

1.07–2.07

0.017*

1045

1.58

1.12–2.22

0.010*

Grade (high vs. low)

1059

1.98

1.53–2.55

< 0.001*

1045

1.34

1.01–1.77

0.042*

Lymphovascular Invasion (yes vs. no)

1068

2.52

1.96–3.24

< 0.001*

1045

1.24

0.92–1.68

0.164

Extramural Venous Invasion (yes vs. no)

1067

2.02

1.56–2.62

< 0.001*

1045

1.41

1.06–1.87

0.019*

MMR Status (pMMR vs. dMMR)

1066

1.13

0.84–1.54

0.421

1045

1.13

0.79–1.61

0.510

AI iTIL Risk (high vs. low)

1070

1.86

1.45–2.39

< 0.001*

1045

1.48

1.13–1.93

0.004*